The company has a platform technology based on a new class of drug candidates that target the acute exacerbations of chronic inflammatory diseases, with the primary aim to stimulate natural healing mechanisms. SynAct Pharma is focused on the development of novel and first in class agonists to target the melanocortin system. The melanocortin system is activated in inflammatory conditions, elicits anti-inflammatory effects, and also stimulates important components of the healing process to aid in the recovery of normal tissue function.
- Bli medlem
- Om SwedenBIO